1. Home
  2. CRSP vs SANM Comparison

CRSP vs SANM Comparison

Compare CRSP & SANM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.70

Market Cap

5.6B

Sector

Health Care

ML Signal

HOLD

Logo Sanmina Corporation

SANM

Sanmina Corporation

HOLD

Current Price

$153.97

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
SANM
Founded
2013
1980
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Electrical Products
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.2B
IPO Year
2016
1993

Fundamental Metrics

Financial Performance
Metric
CRSP
SANM
Price
$56.70
$153.97
Analyst Decision
Buy
Hold
Analyst Count
19
1
Target Price
$71.50
$120.00
AVG Volume (30 Days)
1.8M
680.8K
Earning Date
02-10-2026
01-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.07
EPS
N/A
4.46
Revenue
$38,337,000.00
$8,128,382,000.00
Revenue This Year
N/A
$75.74
Revenue Next Year
$723.84
$12.92
P/E Ratio
N/A
$34.28
Revenue Growth
N/A
7.40
52 Week Low
$30.04
$63.67
52 Week High
$78.48
$178.39

Technical Indicators

Market Signals
Indicator
CRSP
SANM
Relative Strength Index (RSI) 51.43 49.71
Support Level $54.50 $141.01
Resistance Level $59.18 $177.00
Average True Range (ATR) 2.87 8.53
MACD 0.33 -1.55
Stochastic Oscillator 44.03 35.74

Price Performance

Historical Comparison
CRSP
SANM

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SANM Sanmina Corporation

Sanmina Corp is a provider of integrated manufacturing solutions, components, and after-market services to original equipment manufacturers in the communications networks, storage, industrial, defense and aerospace end markets. The operations are managed as two businesses: Integrated Manufacturing Solutions, which consists of printed circuit board assembly and represents a majority of the firm's revenue; and Components, Products, and Services, which includes interconnect systems and mechanical systems. The firm generates revenue primarily in the United States, China, and Mexico, but has a presence around the world.

Share on Social Networks: